Central memory CD8 ؉ T cells (TCM) and effector memory CD8
A doptive cancer immunotherapy, the infusion of tumorreactive T cells to patients, represents a promising approach for the treatment of advanced metastatic disease (1, 2) . To date, cell types with effector T cell (T EFF ) and effector memory CD8 ϩ T cell (T EM ) phenotype and function have been the cells targeted for transfer because of their strong lytic capacity and release of high levels of IFN-␥ (3, 4) . Although transfer of polyclonal tumor-reactive T EFF can cause an objective response rate approaching 50% (5) , there are reasons to believe that transfer of cells with memory properties, including a heightened recall response and the ability to undergo self-renewal, may be superior mediators of an antitumor response (6, 7) .
The T cell memory compartment can be subdivided into two populations, central memory CD8
ϩ T cells (T CM ) and T EM , on the basis of phenotypic markers, functional attributes, and migratory properties (7) . CD62L and CCR7, two surface molecules necessary for cellular extravasation in high endothelial venules, are constitutively expressed by T CM , whereas these markers are significantly down-regulated on T EM . T CM have been shown to be superior to T EM in conferring protective immunity against viral or bacterial challenge (8, 9) . However, the extent to which these results can be generalized has been questioned (10) , and the potential of T CM to treat an established infection or cancer has not been evaluated.
To assess the in vivo role of different CD8 ϩ T cell memory subsets, we used an established in vitro culture system by using IL-15 and IL-2 to generate T CM and T EM, respectively (8, (11) (12) (13) . To generate tumor-reactive CD8 ϩ T cells, we used cells from pmel-1 T cell receptor transgenic mice. Pmel-1 mice have CD8 ϩ T cells that have specificity for a D b -restricted epitope corresponding to amino acid positions 25-33 of the nonmutated self͞tumor antigen (Ag) gp100 (14) . The two cell subtypes were verified by using global analysis of gene expression as well as phenotypic and functional characteristics. We found that adoptive cell transfer (ACT) of self͞tumor-reactive CD8 ϩ T CM was a superior mediator of tumor treatment compared with T EM .
Materials and Methods
Mice and Tumor Lines. Pmel-1 T cell receptor transgenic mice expressing CD8 ϩ T cells with specificity for a D b -restricted epitope from the nonmutated self͞tumor Ag gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] (14) were crossed with C57BL͞6-thy1.1 transgenic and C57BL͞6-Sell Ϫ/Ϫ mice (both from The Jackson Laboratory) to derive pmel-thy1.1 (deposited at The Jackson Laboratory, www.jax.org) and pmel-CD62L Ϫ/Ϫ (pmel CD62L knockout) mice (26) , respectively. Female C57BL͞6 and B6.129S2-Lta tm1Dch ͞J (both from The Jackson Laboratory) and ␤ 2 -microglobulin (␤ 2 M)-deficient (␤ 2 M Ϫ/Ϫ ) mice (Taconic Farms) were used as recipients in ACT experiments. B16 (H-2 b ), a spontaneous gp100 ϩ murine melanoma, has been described (14) . Experiments were conducted with the approval of the National Cancer Institute Animal Use and Care Committee.
TCM and TEM Generation and Adoptive Immunotherapy. Pmel-1 splenocytes were isolated and cultured in the presence of 1 M human gp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] (hgp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] ) and complete medium containing 10 ng͞ml of either recombinant human IL-2 (Chiron) to generate pmel T EM or recombinant human IL-15 (PeproTech, Rocky Hill, NJ) to generate pmel T CM (12) . Mice (n ϭ 5) were injected s.c. with 2-5 ϫ 10 5 B16-F10 melanoma cells. Nine days later, mice were treated with i.v. ACT of pmel T CM or T EM . Where specified, transient lymphopenia was induced by sublethal irradiation (500 cGy) of tumor-bearing mice on the day of treatment. Vaccination was achieved with 2 ϫ 10 7 plaqueforming units of a recombinant fowlpox virus encoding hgp100
Abbreviations: Ag, antigen; hgp100, human gp100; rFPhgp100, recombinant fowlpox virus encoding hgp100; TEM, effector memory CD8 ϩ T cells; TCM, central memory CD8 ϩ T cells; LN, lymph node; ACT, adoptive cell transfer; DC, dendritic cell; CFSE, carboxyfluorescein diacetate succinimidyl ester; LT␣, lymphotoxin-␣; ␤2M, ␤2-microglobulin; BM, bone marrow.
(rFPhgp100) as described (Therion Biologics, Cambridge, MA) (14) . Recombinant human IL-2 was administered by i.p. injection twice daily at 36 g per dose for a total of six doses. Murine bone marrow (BM)-derived dendritic cells (DCs) were generated as described (15) . The products of the perpendicular diameters (mean Ϯ SEM) of tumors for tumor growth curves were measured in a blinded fashion with calipers. All experiments were repeated at least twice with similar results.
Microarray and Flow Cytometric Analysis of TCM and TEM. Pmel T CM and T EM were isolated to a purity of Ͼ95% by using a no-touch, negative selection CD8-enrichment column (Miltenyl Biotech, Auburn, CA). RNeasy column (Qiagen, Germantown, MD)-purified RNA was indirectly labeled with a single round of linear amplification with Amino Allyl MessageAmp reagents (Ambion, Austin, TX). Labeled samples were combined and hybridized overnight to 22,000-gene long-oligo arrays supplied by the National Cancer Institute (Frederick, MD). Data image files were obtained with a GenePix 4000B scanner (Axon Instruments, Union City, CA) and imported into GENESPRING 6.2 software (Silicon Genetics, Redwood City, CA).
Ex Vivo Analysis of Adoptively Transferred Cells. All antibodies were purchased from BD Pharmingen except anti-human granzyme B-phycoerythrin (GB11) (Caltag, Burlingame, CA). FACScalibur f low cytometer and CELLQUEST software (BD BioSciences, Franklin Lakes, NJ) were used to analyze cells. Adoptively transferred cells in inguinal, axillary, and mesenteric lymph nodes (LNs) were analyzed by cytof luorometry for carboxyf luorescein diacetate succinimidyl ester (CFSE), thy1.1, and CD8. For immunohistochemical staining, inguinal LNs were snap-frozen, stored at Ϫ80°C, then sectioned at 7-m cuts by using cryostat. Sections were Fc-blocked before staining with 10 g͞ml purified anti-PNAd (BD Pharmingen) followed by Cy5-conjugated secondary antibody (Caltag). Sections were mounted with a ProLong Antifade Kit (Molecular Probes) and allowed to stand at room temperature overnight. Images were obtained on a Nikon Eclipse confocal laser-scanning microscope (Bio-Rad). In vitro proliferation of pmel T EM and T CM was evaluated by labeling cells with 1 M CFSE (Molecular Probes) and restimulating with 1 M hgp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] -pulsed irradiated splenocytes in complete medium containing 2 ng͞ml of recombinant human IL-2.
In Vitro Rolling Assay. Rolling of pmel T EM , pmel T CM , and CD8-enriched naïve cells was determined on 35-mm cell suspension plates (430588) (Corning) coated with GlyCAM-1 (a gift from S. D. Rosen, University of California, San Francisco), E-selectin (R & D Systems), or 1% BSA in PBS, held overnight at 4°C, and blocked with 1% BSA for 1 h at 4°C. Calceinacetomethyl-labeled (Molecular Probes) T cells were injected at 1.5 dynes per cm 2 into a parallel plate flow chamber (Glycotech, Gaithersburg, MD). Cells were digitally photographed (Ϸ1 image per s) in four to six random fields (each field ϭ 1.18 mm 2 ) with excitation at 488 nm and emission at 513 nm, and nonmoving and moving cells were differentiated with the IPLAB software program (Scanalytics, Fairfax, VA) and compared by using the Student t test. Redundancy of lymphoid-homing molecules. Splenocytes from pmel-CD62L Ϫ/Ϫ or age-matched pmel-CD62L ϩ/ϩ controls were stimulated with 1 M hgp10025-33 peptide and cultured under TEM conditions. Cells were cytofluorometrically analyzed on day 6 for the expression of integrin ␣E, integrin ␤7, and CCR7. Numbers represent the percentage of gated cells in each quadrant after gating on propidium iodide-negative and CD8 ϩ lymphocytes. (D) Tumor treatment fails in ␤2M Ϫ/Ϫ hosts, but can be rescued by cotransfer of BM-derived DCs. WT or ␤2M Ϫ/Ϫ mice bearing 9-day B16 tumors were left untreated as controls (F and E, respectively) or received 1 ϫ 10 6 TEM pmel, rFPhgp100, and exogenous IL-2 (■ and ᮀ, respectively) Ϯ cotransfer of mature BM-derived DCs (OE).
Results

Trafficking to 2°Lymphoid Tissues Is Required for Optimal Antitumor
Treatment. Altered peptide ligand (14, 15) vaccine-encoded tumor Ag presentation by professional Ag-presenting cells promotes optimal antitumor immunity (16). We therefore hypothesized that trafficking of adoptively transferred cells to 2°l ymphoid organs could lead to an enhanced in vivo antitumor response. To evaluate the lymphoid trafficking requirements of adoptively transferred pmel cells, we compared the tripartite treatment regimen of cells, rFPhgp100 vaccination, and exogenous IL-2 in tumor-bearing C57BL͞6 (WT) and lymphotoxin-␣ Ϫ/Ϫ (LT␣ Ϫ/Ϫ ) mice. LT␣ Ϫ/Ϫ mice lack peripheral lymphoid structures, including LNs and mucosal Peyer's patches, and possess a disorganized splenic white pulp (17) . To provide a treatment window, we intentionally transferred a noncurative dose (1 ϫ 10 6 ) of pmel T EM . There was no statistical difference in tumor growth between untreated WT and LT␣ Ϫ/Ϫ mice (P ϭ 0.8550) (Fig. 1A) . As previously shown by our group, the combination of pmel T EM , vaccination, and IL-2 caused a pronounced delay in tumor growth in WT mice compared with untreated controls (P Ͻ 0.0001) (12, 14, 18) . By contrast, the antitumor effect was completely abrogated in LT␣ Ϫ/Ϫ mice. There was no statistical difference in tumor growth between untreated LT␣ Ϫ/Ϫ mice and LT␣ Ϫ/Ϫ mice that received cells, vaccine, and IL-2 (P ϭ 0.6200). Thus, 2°LNs were required in the tumor-bearing host for optimal tumor treatment.
To determine the influence of L-selectin (CD62L), a critical mediator of lymphocyte homing to 2°LNs (19), we adoptively transferred T EM from pmel-CD62L Ϫ/Ϫ or age-matched pmel-CD62L ϩ/ϩ controls in combination with vaccine and IL-2 into tumor-bearing WT mice. Although treatment with either T EM pmel-CD62L Ϫ/Ϫ or pmel-CD62L ϩ/ϩ cells resulted in delayed tumor growth compared with untreated controls (P ϭ 0.0018 and Ͻ 0.001, respectively), pmel-CD62L ϩ/ϩ cells conferred superior treatment efficacy compared with pmel-CD62L Ϫ/Ϫ cells (P ϭ 0.0091) (Fig. 1B) . Thus, CD62L was functionally important for antitumor T cell function in vivo. Phenotypic analysis revealed, however, that the overexpression of other LN-homing receptors might partially compensate for the lack of CD62L, including integrin ␤ 7 , integrin ␣E, and CCR7 (Fig. 1C) . To test whether homing of adoptively transferred pmel-1 cells to LNs facilitated their interaction with resident professional Ag-presenting cells expressing the vaccine-encoded hgp100 [25] [26] [27] [28] [29] [30] [31] [32] [33] , we compared the treatment efficacy of our tripartite regimen in tumor-bearing WT versus ␤ 2 M Ϫ/Ϫ mice. Tumor growth was identical in untreated WT and ␤ 2 M Ϫ/Ϫ controls (P ϭ 0.963) (Fig.  1D) . The tripartite regimen of cells, vaccine, and IL-2 was effective at delaying tumor growth in WT mice (P ϭ 0.0034) but was not effective in the same experiment in mice incapable of presenting MHC class I-restricted Ags (untreated vs. treated ␤ 2 M Ϫ/Ϫ mice P Ͼ 0.05). This lack of treatment effect could be partially rescued by the cotransfer of ␤ 2 M-intact mature BMderived DCs (P ϭ 0.009 vs. no treatment). No rescue was observed when DCs were generated from ␤ 2 M Ϫ/Ϫ mice (data not shown). Thus, we determined that trafficking of adoptively transferred tumor-reactive CD8 ϩ T cells to organized 2°lym-phoid tissues was necessary for optimal in vivo antitumor efficacy in a combined immunotherapy treatment regimen that includes tumor-Ag vaccination.
Gene Expression Profiling of CD8 ؉ T CM vs. T EM . Because trafficking to 2°lymphoid tissues by adoptively transferred pmel cells facilitated their in vivo antitumor efficacy, we sought to create T cells with enhanced LN-homing attributes. Naïve, peptidestimulated CD8 ϩ T cells expanded in the presence of IL-15 give rise to in vitro differentiated T CM , whereas IL-2 caused the expansion of T EM that lost the expression of the LN-homing markers CD62L and CCR7 (8, 12, 13) . To more fully characterize the attributes of these two cell populations, we performed microarray analysis (GEO accession nos. GSE2578 and GSM49518, www.ncbi.nlm.nih.gov͞geo). A total of 476 of the 22,000 genes sampled were differentially expressed between pmel T CM and T EM . Remarkably, genes associated with homing to 2°lymphoid tissues, including integrin aE, cd62l, ly6c, cxcr3, and ccr7, were among those RNAs overexpressed by pmel T CM compared with T EM (Fig. 2A) . Additionally, mcl1, an antiapoptosis molecule implicated in the maintenance of mature T lymphocytes, was also up-regulated by T CM (20) . By contrast, genes associated with effector functions (granzyme A, B, C, D, F, G, H, and perforin) and proapoptotic signaling (Bid, Bnip3, and Bad) were among the most highly overexpressed in T EM (Fig.  2 A) . Microarray results for CD62L, integrin ␣E, and intracellular granzyme B on pmel T CM and T EM were validated by cytofluorometry (Fig. 2B) . Consistent with previously published FACS results, CD62L expression was notably higher in pmel T CM than in T EM (12) . Integrins ␣E (Fig. 2B ) and ␤ 7 (data not shown) were two additional lymphoid-homing molecules that were overexpressed on pmel T CM . Conversely, pmel T EM exhibited a higher level of granzyme B expression compared with pmel T CM (mean fluorescence intensity ϭ 998 and 499, respectively). These data indicated that some of the most pronounced gene and protein expression differences between pmel T CM and T EM relate to the capacity to home to LNs and the acquisition of effector functions, respectively.
In Vitro and in Vivo LN-Homing Attributes of Tumor Ag-Specific TCM and TEM. To determine whether the gene and protein expression profiling results of pmel T CM and T EM were reflected in functional difference in tissue homing behavior, we evaluated the in vitro rolling of pmel T CM and T EM under physiologic shear flow conditions. We used substrates coated with glycam-1, a ligand for CD62L expressed in the high endothelial venules of peripheral LNs (19) . Neither population of cells rolled on substrates coated with BSA, an irrelevant protein control (Fig. 3A) . Both pmel T CM and CD8-enriched naïve pmel-1 cells, a lymphocyte population with optimal LN-homing attributes, rolled on glycam-1, whereas pmel T EM did not (P Ͻ 0.01) (Fig. 3 A and B) . T EM reportedly display a characteristic pattern of surface chemokine and adhe- sion molecules required for homing to inflamed peripheral tissues (7) . To test this capacity, we assayed rolling of in vitro-generated pmel T CM and T EM on substrates coated with E-selectin, a leukocyte adhesion molecule expressed on endothelial cells at inflammatory sites. Both cell types rolled on this substrate (Fig. 3A) ; however, a greater number of pmel T EM compared with T CM was found on E-selectin (P Ͻ 0.05). Therefore, pmel T EM possessed in vitro properties consistent with an enhanced propensity to traffic to inflamed peripheral tissues, whereas pmel T CM displayed enhanced LN-homing attributes.
We next investigated the in vivo LN-homing properties of these two cell populations. We adoptively transferred CFSElabeled pmel-thy1.1 T CM and T EM into thy1.2 C57BL͞6 hosts. Twenty-four hours after ACT, we extracted peripheral LNs of recipient mice for immunohistochemical staining and FACS analysis. Grossly, immunohistochemical staining of inguinal LNs 24 h after ACT revealed a pronounced accumulation of adoptively transferred CFSE-labeled cells in animals that received pmel T CM , but not T EM (Fig. 3C) . Cytofluorometric analyses of peripheral LNs was performed to quantitate these results, and multiple independent experiments confirmed that there was between 20 and 40 times the number of CFSE ϩ CD8 ϩ cells present in lymphoid tissues in animals that received pmel T CM compared with T EM (Fig. 3D) . These results were not caused by differential CFSE dilution by pmel T EM because similar results were obtained by analysis for CD8 ϩ Thy1.1 ϩ cells (data not shown). These data demonstrated that gene expression profiling of pmel-1 cells expanded under T CM and T EM conditions accurately depicted the in vitro and in vivo LN-homing attributes of these two populations of tumor-reactive CD8 ϩ T cells.
Enhanced in Vivo Recall Response and Tumor Treatment of TCM
Compared with TEM. To determine the functionality of T CM and T EM in vivo, we adoptively transferred in vitro-differentiated pmel subsets into sublethally irradiated tumor-bearing WT mice in combination with vaccine and IL-2. The in vivo recall response of these two cell populations (as assessed by the enumeration of the absolute numbers of adoptively transferred pmel-1 cells in the spleens and blood of treated animals) revealed that there was a marked expansion of adoptively transferred T CM and T EM , peaking in both groups Ϸ5 days after transfer (Fig. 4A) . Importantly, the magnitude of the response in the spleens of mice that received T CM was strikingly greater, peaking at levels four to 14 times higher than T EM in individual experiments. These results were not caused simply by the differential accumulation of T CM in the spleen because an analogous proliferation pattern was also observed in the blood, a nonlymphoid tissue (Fig. 4 B and C) . Indeed, animals that received T CM experienced a true tumorreactive CD8 ϩ T cell lymphocytosis that was more than three times the absolute lymphocyte count of WT mice, a phenomenon not observed with T EM . The in vivo results were not caused merely by intrinsic differences in proliferative capacity of T CM over T EM , because there was a similar rate of CFSE dilution in these two cell populations in an ex vivo assay (Fig. 4D) .
Pronounced lymphocytosis in melanoma patients treated with ACT after lymphodepletion has been correlated with antitumor efficacy (5) . To determine whether the lymphocytosis observed in mice treated with T CM correlated with the antitumor effect, we treated sublethally irradiated mice bearing 9-day established B16 melanoma with ACT at a dose of pmel cells (1 ϫ 10 6 ) previously established to be noncurative when T EM are used in combination with vaccine and IL-2. As previously shown, the suboptimal tripartite regimen using pmel T EM caused a pronounced delay without cures in tumor growth compared with untreated controls (P ϭ 0.0069) (Fig. 5A) . Treatment with T CM delayed tumor growth significantly compared with both untreated controls (P Ͻ 0.0001) and T EM -treated mice (P ϭ 0.0014). In addition, a T CM -based regimen caused improved survival (P Ͻ 0.002) (Fig. 5B) . Thus, ACT of a T CM population, in combination with tumor-Ag vaccination and exogenous IL-2, produced a more robust and therapeutically significant in vivo recall response compared with T EM .
Discussion
Recent human trials for the adoptive immunotherapy of cancer have demonstrated a statistical correlation between the persistence of transferred tumor-reactive T cells and the therapeutic response that could objectively be achieved in Ϸ50% of the patients treated by using cells with T EM or effector T cell phenotype (21) . Although preliminary work using viral Ags has suggested that T CM are superior mediators of a recall response to Ag challenge (8, 9) , some have recently called these findings into question (10) . In the present studies, we evaluated the role of T EM and T CM populations as mediators of an immune response to an established disease. We found that Ag-specific T CM mounted a heightened in vivo recall response compared with T EM , consistent with other reports (9, 22) . Importantly, this enhanced response by T CM was associated with the complete eradication of a large, established B16 melanoma. As seen in other models, T EM can generate a 2°response but the relative efficiency of this response was less than that of T CM on a per-cell basis (9, 22) .
Although T CM and T EM have been subdivided on the basis of their relative expression of lymphoid-homing molecules (7, 11) , these two populations also possess other unique attributes. For example, T EM have been shown to develop effector functions more rapidly than T CM (7, 8) . By contrast, T CM are able to release significant amounts of helper cytokines, such as IL-2 (7, 9, 12). In our own analysis of the differences between T CM and T EM by using oligo microarrays, we found that expression of genes associated with lymphoid homing were among the most highly overexpressed by T CM . The critical importance of homing to 2°L
Ns by adoptively transferred tumor-reactive T cells was established by experiments in which tumor therapy was completely abrogated in host mice with absent peripheral lymphoid tissues and a disrupted splenic structure. Further evidence that trafficking to LNs is required was provided by using tumor-reactive CD8 ϩ T cells genetically deficient in CD62L. T cell homing to 2°LNs was required to facilitate interaction with virally infected BM-derived Ag-presenting cells, as evidenced by the absence of tumor treatment in ␤ 2 M Ϫ/Ϫ hosts and their rescue by cotransfer of WT BM-derived DCs. It is likely that the enhanced in vivo proliferative response of T CM was the result of increased access to vaccine-encoded Ag-expression in 2°LNs as both T CM and T EM exhibited similar intrinsic proliferative responses when Ag levels were normalized in vitro. These results indicated that, in addition to prevention, T CM can be a superior mediator of a therapeutic response, and this effect highly depended on the cells' homing to lymphoid tissues.
The approach of targeting T cell trafficking to LNs provides an alternative to attempts to cause the initial trafficking of adoptively transferred immune cells to tumors directly (23) . These efforts have included the insertion of genes encoding chemokine receptors into lymphocytes to enhance their recruitment to tumor sites (24) and the genetic modification of the tumor microenvironment itself through the forced expression of LIGHT, a tumor necrosis factor superfamily member used to enhance the recruitment, retention, and activation of T cells (25) . Thus, the alternative and perhaps complementary approach described here is the use of concomitant tumor-Ag vaccination that induces a massive clonal expansion and subsequent infiltration of numerous tissues by antitumor T cells (18) that obviates the requirement for immediate and specific targeting of the tumor site.
These results have implications for the design of human adoptive immunotherapy trials. In most currently used protocols, the cells generated for ACT acquire effector T cell͞T EM phenotypic and functional attributes before transfer (4) . Our data suggest that ACT of these populations may be suboptimal; although response rates approaching 50% can now be obtained with the transfer of very large numbers (up to 1 ϫ 10 11 ) of ex vivo-expanded T cells ( 
